Stanley T. Crooke, M.D., Ph.D.

Stanley T. Crooke, M.D., Ph.D.

Chairman of the Board & Chief Executive Officer

Dr. Crooke is the founder, chairman and chief executive officer of Ionis Pharmaceuticals.  Under his leadership, Ionis pioneered development of the revolutionary antisense technology platform and created one of the largest, most advanced pipelines in the biotechnology industry. Today, Ionis has more than 45 medicines in development, including more than four entering pivotal studies and a larger number in Phase 2 clinical studies.

Commercialization of SPINRAZA®(nusinersen), the standard of care treatment for spinal muscular atrophy, and TEGSEDI(inotersen), the world’s first RNA-targeting subcutaneous injection to treat polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR) in adults, are recent examples of Ionis’ transformational therapies being delivered to patients in need.

Prior to founding Ionis, Dr. Crooke was head of R&D at SmithKline, where he was involved in commercializing numerous drugs in broad therapeutic areas and later assumed responsibility for worldwide R&D at SmithKline Beckman. At Bristol-Myers, he established the first broad anticancer program, bringing nine drugs to the market in five years.

He has led the development of more than 20 marketed drugs and supported the creation and growth of several companies based on Ionis’ antisense technology, including Alnylam and Regulus. He is also on the Board of Directors of the Biotechnology Industry Organization (BIO).

Dr. Crooke is a recipient of the Oligonucleotide Therapeutics Society Lifetime Achievement Award, the American Chemical Society’s E.B. Hershberg Award for Important Discoveries in Medicinally Active Substances, the Prix Galien Best Biotechnology Award for Spinraza, the Scrip Lifetime Achievement Award, and BIO’s Helix Award for the most important innovation.

Dr. Crooke received his M.D. and Ph.D. degrees and house staff training at Baylor College of Medicine and has been an active scientist throughout his career. He has published nearly 500 scientific publications, edited more than 20 books, and has numerous patents.